Rx Product News

Published Online: Monday, November 11, 2013

Marketed by: Takeda Pharmaceuticals America, Inc
Indication: The FDA has approved Kazano (alogliptin and metformin HCl)—a dipeptidyl-peptidase-4 inhibitor and biguanide combination product—as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (DM). Kazano is not indicated for treatment of type 1 DM or diabetic ketoacidosis. The starting dose should be individualized to the patient, but a maximum recommended daily dose of 25 mg alogliptin and 2000 mg metformin HCl should not be exceeded.
Dosage Form: Tablets (mg alogliptin/mg metformin HCl): 12.5/500, 12.5/1000
For More Information: www.takeda.us/products/default.aspx

Marketed by: ViiV Healthcare
Indication: The FDA has approved Tivicay (dolutegravir), an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for treating HIV-1 infection in adults and children 12 years and older and weighing at least 88 lb (40 kg). The recommended dose in treatment-naïve or treatment-experienced INSTI-naïve adults is 50 mg once daily. For pediatric dosing, see the prescribing information. Tivicay may be taken without regard to meals.
Dosage Form: Tablets: 50 mg
For More Information: www.viivhealthcare.com/our-medicines/tivicay.aspx

Marketed by: Ceptaris Therapeutics, Inc
Indication: The FDA has approved Valchlor (mechlorethamine), an alkylating drug indicated for the topical treatment of stages IA and IB mycosis fungoides–type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. The recommended dose is once-daily application of a thin film to affected areas of the skin. Valchlor is for topical dermatologic use only.
Dosage Form: Gel: 0.016% w/w of mechlorethamine (equivalent to 0.02% mechlorethamine HCl) in 60-g tubes
For More Information: www.valchlor.com

Marketed by: Galderma
Indication: The FDA has approved Mirvaso (brimonidine) topical gel, 0.33%, an alpha-adrenergic agonist for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older. The recommended dose is application of a pea-size amount once daily to each of 5 areas of the face (ie, forehead, chin, nose, and each cheek) while avoiding the eyes and lips. Hands should be washed immediately after application.
Dosage Form: Gel, 0.33%: each gram contains 5 mg of brimonidine tartrate
For More Information: www.mirvaso.com

Latest Articles
As today is World AIDS Day, pharmacists across the globe may be renewing their interest in quashing HIV infection and providing support for infected patients.
Pharmacists are in a great position to impart valuable heart-related wisdom to their patients.
Shifts in sleep schedules may increase an individual’s risk for diabetes.
Qualgen has taken corrective actions concerning its compounding facility conditions and sterility processes.
Latest Issues